Global infectious disease therapeutics market is anticipated to grow at a CAGR of 7.8% during the forecast period (2023-2030). The market growth is attributed to the increasing prevalence of HPV, increasing FDA approvals rising supply of free infectious disease self-test kits, and raising awareness campaigns around the globe. According to the WHO, the global pooled prevalence was 31% for any HPV and 21% for high-risk HPV. HPV-16 was the most prevalent HPV genotype (5%) followed by HPV-6 (4%). HPV prevalence was high in young adults, reaching a maximum between the ages of 25 years and 29 years, Additionally, market players are also developing new products to treat infectious diseases and receiving approvals to commercialize their products. In February 2023, Becton, Dickinson, and Company, a global provider of medical technology company, received the US FDA market approval for the BD Onclarity™ HPV assay to be used with the BD SurePath™ Liquid-based Pap Test and Hologic ThinPrep® Pap Test. The BD SurePath™ Liquid-based Pap Test vial and the Hologic ThinPrep® Pap Test PreservCyt® Solution vial are the two most common Pap vials used by laboratories in the US.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/infectious-disease-therapeutics-market
Furthermore, the growing prevalence of malaria around the globe, and increasing funding activities for patients who have infectious diseases also enlarged the demand for infectious disease therapeutics. According to the WHO, malaria mortalities reduced steadily over the period 2000–2019, from 897,000 in 2000 to 577,000 in 2015 and to 568,000 in 2019 around the globe. In 2020, malaria mortalities increased by 10% compared with 2019, to an estimated 625,000. Estimated fatalities declined slightly in 2021 to 619,000. Between 2019 and 2021, 63,000 fatalities were due to disruptions to essential malaria services during the COVID-19 pandemic. Globally, the malaria mortality rate that is deaths per 100,000 population at risk split from about 30 in 2000 to 15 in 2015; it then continued to decrease but at a slower rate, falling to 14 in 2019. In 2020, the mortality rate increased again, to 15.1, before decreasing slightly to 14.8 in 2021.
Total funding for malaria control and elimination in 2021 was estimated at $3.5 billion, compared with $ 3.3 billion in 2020 and $3.0 billion in 2019. The amount invested in 2021 fell short of the $7.3 billion estimated to be required to stay on track toward the GTS milestones around the globe.
Market Coverage
- The market number available for – 2022-2030
- Base year- 2022
- Forecast period- 2023-2030
- Segment Covered-
o By Disease Type
o By End-user
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
Competitive Landscape- includes, Novartis AG, Gilead, GlaxoSmithKline plc, Janssen Pharmaceutical, Inc., F. Hoffmann-La Roche Ltd., BioCryst Pharmaceuticals Inc., and others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Infectious Disease Therapeutics Market Report Segment
By Disease Type
- Human immunodeficiency viruses (HIV),
- Tuberculosis (TB),
- Influenza,
- Hepatitis,
- Human papillomavirus (HPV)
- Malaria
By End-User
- Hospital
- Clinics
A full report of Infectious Disease Therapeutics Market available @ https://www.omrglobal.com/industry-reports/infectious-disease-therapeutics-market
Global Infectious Disease Therapeutics Market Report Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Amgen Inc.
- Aspen Pharmacare Holdings Ltd.
- Boehringer Ingelheim GmbH
- Celltrion, Inc.
- Cidara Therapeutics, Inc.
- CureVac SE
- GeoVax, Inc.
- Hookipa Pharma Inc.
- Janssen Pharmaceutical (Johnson & Johnson)
- Lupin Pharmaceuticals, Inc.
- Merck & Co., Inc.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
